BERLIN (Reuters) -Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would ...

Have you ever hoped your dog could live a little bit longer? Now, pet owners are one step closer after an anti-aging pill for ...

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

Wilson Community College is building a biotechnology and workforce center to prepare students for jobs in the biotech ...

A vow by the agency’s new commissioner, Marty Makary, to support innovation might ease fears stoked by Health and Human ...

It’s been a volatile few years for Neuren, the neurological disorder treatment group which has seen shares rocket, then slump ...

Biotech entrepreneur Sam Waksal has been accused of "reckless conduct," including using a veterinary medicine on a severely ...

Switzerland's Xlife Sciences AG said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition in a deal that will value the combined company at $1.64 billion.

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

The biotech mergers and acquisitions market faces significant headwinds in the first half of 2025. These challenges include frozen capital ...